Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This prestigious 3-year Fellowship (formerly Oxford-Celgene Fellowship) aims to stimulate new scientific discovery and translation and to facilitate skills and people transfer between researchers in academia and industry.

Bristol Myers Squibb (BMS) is a global biopharmaceutical company making advancements in oncology, haematology, immunology and cardiovascular disease. BMS are dedicated to helping patients prevail over serious diseases through a diverse and promising pipeline and new scientific platforms. 

BMS acquired Celgene in 2019. Prior to 2019, in partnership with the Oxford Medical Sciences Division, Celgene co-developed and provided support for fellowships which will continue as the Oxford-BMS Translational Research Fellowship Programme. 

The goals of this scheme are to stimulate new scientific discovery and translation and to facilitate skills and people transfer between researchers in academia and industry.  

This programme offers fellows an opportunity to gain exposure to the field of commercial drug discovery and development. Fellows will have an assigned company mentor and where appropriate be encouraged to spend some time based in BMS laboratories.

Funding will be awarded to Oxford Principal Investigators to support 3 year fellowship projects for early career researchers that demonstrate a clear translational value to the advancement of therapeutics. Three to four awards are made annually.

Currently there are 24 fellows working with BMS and you can read about their projects here

Principle Investigators should apply for fellowship funding to support clinical (Grade E64) or basic research scientists (Grade 7/8) committed to translational science and interested in obtaining experience with drug development in an industrial setting. 

Fellowship applications may include a named fellow, but this is not mandatory. It is expected that a suitable fellowship candidate will be identified by the Principle Investigator within 6 months of notification of successful project selection.

The proposed fellowship needs to align with BMS’s fields of interest as listed below.

1. Novel targets, biomarkers, cellular therapeutic approaches, or translational models in one of the following areas:

  • immuno-oncology;
  • neurodegenerative and neuroinflammatory diseases including Alzheimer’s, Parkinson’s, ALS, FTD and MS;
  • fibrosing disorders including IPF, NASH, scleroderma, and Renal Fibrosis;
  • rheumatic and dermatologic disorders including RA, SLE, spondyloarthropathies, psoriasis and atopic dermatitis; 
  • haematologic disorders including AML, Myeloma, DLBCL;
  • chronic heart failure (either with preserved or reduced ejection fraction).

2. Methods for evaluating biochemical, cellular, tissue and phenotypic consequences of
modulating epigenetic targets.

3. Methods for immuno-phenotyping of human subjects in oncology and autoimmunity

4. Novel imaging approaches to measuring disease activity in the above areas.

now open for new applications - december 2020

Prospective Principle Investigator applicants should read this application guidance

Stage 1 - Pre-application and meeting with BMS

The Oxford-BMS Fellowship Programme strongly encourages you to take pre-application steps before submitting your full application.

The pre-application steps ensure that your proposal is in line with BMS’s areas of research interest and involves a pre-application form and a meeting with BMS (held virtually). 

Stage 2 - Full application

Full applications are made on the full application form and should be emailed, along with the draft X5 costing to 

Please consult the guidance document for details on the application process. 

Come along to one of four information session to find out how to apply for an Oxford-Bristol Myers Squibb (formerly Celgene) Fellowship. We will talk you through the background to the fellowships scheme, give details about BMS areas of interest and explain the application process. This will be followed by a Q&A session.


The 2021 competition has now closed.

Please check this webpage in December 2021 for details of future competitions.

For all enquiries please contact Charlotte Bell, Business Partnerships Manager, Medical Sciences Division, Business Partnerships Office


Telephone: 01865 289877


Professor Sir Marc Feldmann (Oxford)

Professor Fiona Powrie (Oxford)

Professor Irene Tracey (Oxford)

Professor Chas Bountra (Oxford)

Dr. Maxine Allen (Oxford)

Dr. Rupert Vessey (BMS)

Dr. Leon Carayannopoulos (BMS)

Dr. James Carmichael (BMS)

Dr. Anjan Thakurta (BMS)

 Current Fellows

Nora Bengoa-Vergniory Liam Brown Pablo Cespedes smiling

Nora Bengoa-Vergniory

Liam Brown

Pablo Cespedes

'Inhibition of alpha-synuclein aggregation and glial activation as a therapeutic strategy for Parkinson’s disease'

'A computational framework for T cell trafficking and dynamics in anti-tumour immune responses'

'Studying the effects of citrullination on the dynamics of receptor-ligand pair interactions at the Immune Synapse'

PI: Richard Wade-Martins

 PI: Mark Coles, Eamonn Gaffney


Hebe Chen smiling Liliana Cifuentes Image credit: Medical Sciences Division and John Cairns

Hebe Chen

Liliana Cifuentes

 Amy Cross

'Investigation of epigenetic and post-translational modifications in altered STAT3'

'Protein kinase C-θ and PD-1 as a therapeutic target in inflammatory arthritis'

'Combination therapy of low dose regulatory T cells and low dose IL-2 to prevent rejection in transplantation'

PI: Professor Holm Uhlig & Dr. Arian Laurence

PI: Graham Ogg, Peter Taylor, Mike Dustin

PI: Dr Joanna Hester & Dr Fadi Issa

Ruxandra Dafinca Melanie Dunstan Michael Fitzpatrick

Ruxandra Dafinca

Melanie Dunstan

Michael Fitzpatrick

'Targeting intracellular trafficking and nucleocytoplasmic transport in mouse and human motor neurons carrying ALS mutations in TDP-43'

'Ultra low-dose IL-2 therapy in autoimmune diabetes'

'Use of unbiased T-cell receptor repertoire sequencing to identify novel T-cell subsets involved in coeliac disease and increase the accuracy of the diagnosis of gluten sensitivity'

 PI: Kevin Talbot

PI: John Todd, Claudia Monaco

 PI: Elizabeth Soilleux, Paul Klennerman

Stefania Giussani

Image of Sarah Gooding

Tariq Khoyratty

Stefania Giussani

 Sarah Gooding

 Tariq Khoyratty

'Investigation of T cell reactivity to alpha-synuclein in Parkinson's disease'

 'Determining changes in clonal/sub clonal architecture and relation to immune marrow environment enabling tumour persistence/relapse in myeloma'

 'Defining an early signature of neutrophil extracellular trap formative predictive of responses to PAD4/2 inhibitors in rheumatic patients'


PI: Paresh Vyas, Udo Oppermann, Karthik Ramasamy

PI: Irina Udalova, Raashid Luqman

Kate Lines Sarah Sasson

Kate Lines

Sarah Sasson


'Targeting Epigenetic Mechanisms for the Treatment of Pancreatic Neuroendocrine Tumours'

'Checkpoint blockade-mediated autoimmune colitis as a model for gut immune homeostasis'


PI: Rajesh Thakker  PI: Paul Klenerman, Oliver Brain  



Past Fellows


Hannah Chen Thomas Layton Heidi Olzscha.png

Hannah Chen

Thomas Layton

Heidi Olzscha

'Definition of new drug targets for fibrosis in Crohns'

'Single cell analysis of the fibrotic landscape in Dupuytren's Disease'

'Unravelling the role of E2F-1 citrullination in inflammatory disease'                                         

PI: Alison Simmons

PI: Jagdeep Nanchahal

PI: Nick La Thangue

Lynn Quek.png



Lynn Quek



'Clonal and Functional heterogeneity in AG221-treated IDH2 mutant Acute Myeloid Leukaemia'



PI: Paresh Vyas